Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
SNY's Cash to Debt is ranked higher than
95% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. SNY: No Debt )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Interest Coverage 8.34
SNY's Interest Coverage is ranked higher than
85% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.63 vs. SNY: 8.34 )
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 8.34

7.88
19.65
WACC vs ROIC
7.42%
14.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 17.28
SNY's Operating margin (%) is ranked higher than
88% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.10 vs. SNY: 17.28 )
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 17.28

15.25
38.21
Net-margin (%) 12.27
SNY's Net-margin (%) is ranked higher than
86% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. SNY: 12.27 )
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.27

7.92
25.8
ROE (%) 14.97
SNY's ROE (%) is ranked higher than
86% of the 895 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. SNY: 14.97 )
SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 14.97

5.18
33.55
ROA (%) 8.68
SNY's ROA (%) is ranked higher than
86% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. SNY: 8.68 )
SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 8.68

2.62
21.59
ROC (Joel Greenblatt) (%) 69.54
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. SNY: 69.54 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.28   Max: 145.55
Current: 69.54

31.28
145.55
Revenue Growth (3Y)(%) 0.50
SNY's Revenue Growth (3Y)(%) is ranked lower than
54% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. SNY: 0.50 )
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.5   Max: 27.4
Current: 0.5

0.5
27.4
EBITDA Growth (3Y)(%) -2.00
SNY's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. SNY: -2.00 )
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -2   Max: 35.7
Current: -2

-2
35.7
EPS Growth (3Y)(%) -12.80
SNY's EPS Growth (3Y)(%) is ranked higher than
50% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. SNY: -12.80 )
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.8   Max: 41.2
Current: -12.8

-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SNY Guru Trades in Q1 2014

Scott Black 247,100 sh (New)
Bill Nygren 2,600,000 sh (New)
John Buckingham 20,080 sh (New)
Steven Cohen 300,000 sh (New)
Manning & Napier Advisors, Inc 2,923,087 sh (+836.86%)
HOTCHKIS & WILEY 9,804,594 sh (+65.83%)
James Barrow 27,790,116 sh (+22.72%)
Sarah Ketterer 506,901 sh (+17.52%)
PRIMECAP Management 2,476,856 sh (+8.58%)
Charles Brandes 2,072,790 sh (+2.95%)
Ken Fisher 12,926,402 sh (+0.84%)
Dodge & Cox 43,664,887 sh (+0.08%)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
John Hussman 22,100 sh (unchged)
Third Avenue Management 15,706 sh (-2.48%)
NWQ Managers 5,460,055 sh (-6.39%)
Jean-Marie Eveillard 610,749 sh (-6.68%)
» More
Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.3%)
Ken Fisher 13,079,575 sh (+1.18%)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
Jean-Marie Eveillard 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
Jean-Marie Eveillard 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

Steven Cohen 1,050,000 sh (New)
David Dreman 1,102 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
Jean-Marie Eveillard 34,157 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2014-12-31 Add 18.16%0.29%$44.4 - $55 $ 48.360%11692693
NWQ Managers 2014-12-31 Add 22.12%0.29%$44.4 - $55 $ 48.360%2941923
NWQ Managers 2014-12-31 Add 22.12%0.29%$44.4 - $55 $ 48.360%2941923
Charles Brandes 2014-12-31 Add 14.36%0.21%$44.4 - $55 $ 48.360%2571795
James Barrow 2014-12-31 Add 8.87%0.15%$44.4 - $55 $ 48.360%30804459
David Dreman 2014-12-31 New Buy$44.4 - $55 $ 48.360%1102
Bill Nygren 2014-09-30 Add 14.55%0.27%$50.89 - $57.29 $ 48.36-10%5670000
Jean-Marie Eveillard 2014-09-30 Reduce -94.39%0.07%$50.89 - $57.29 $ 48.36-10%34157
PRIMECAP Management 2014-09-30 Add 29.21%0.05%$50.89 - $57.29 $ 48.36-10%3891356
NWQ Managers 2014-06-30 Reduce -52.34%1.31%$51.23 - $54.54 $ 48.36-9%2602503
Bill Nygren 2014-06-30 Add 90.38%0.9%$51.23 - $54.54 $ 48.36-9%4950000
Scott Black 2014-06-30 Reduce -27.57%0.39%$51.23 - $54.54 $ 48.36-9%178985
John Hussman 2014-06-30 Sold Out 0.09%$51.23 - $54.54 $ 48.36-9%0
PRIMECAP Management 2014-06-30 Add 21.59%0.03%$51.23 - $54.54 $ 48.36-9%3011646
Scott Black 2014-03-31 New Buy1.4%$47.77 - $53.63 $ 48.36-4%247100
Bill Nygren 2014-03-31 New Buy1.1%$47.77 - $53.63 $ 48.36-5%2600000
HOTCHKIS & WILEY 2014-03-31 Add 65.83%0.75%$47.77 - $53.63 $ 48.36-5%9804594
James Barrow 2014-03-31 Add 22.72%0.39%$47.77 - $53.63 $ 48.36-5%27790116
NWQ Managers 2014-03-31 Reduce -6.39%0.17%$47.77 - $53.63 $ 48.36-5%5460055
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
sing the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were held by the highest number of gurus. Read more...
Oakmark Funds' Bill Nygren Buys 4 New Stocks
Bill Nygren (Trades, Portfolio)’s Oakmark fund beat the S&P 500 for the first quarter with a 5% gain compared to the index’s 2% rise. In his first quarter letter, he attributed the strong quarter primarily to Forest Laboratories being acquired by Actavis Plc (ACT), and large exposure to auto-related cyclical and financials. Read more...
Bill Nygren Comments on Sanofi
Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%. Read more...
Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were bought by the highest number of gurus. Read more...
Warren Buffett Shows Changes to International Stocks: Tesco, Munich Re, Sanofi, POSCO
Warren Buffett (Trades, Portfolio) reported the holding changes at Berkshire Hathaway (BRK.A)(BRK.B) last month, but he did not include his foreign stocks, as he is not required to by the SEC. Once a year, in his annual letters, however, he gives a glimpse of his international dealings by reporting the status of all his equity positions exceeding $1 billion in value. The latest letter, reported last week, revealed some notable changes in his international holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.20
SNY's P/E(ttm) is ranked higher than
85% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.60 vs. SNY: 28.20 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 402.35
Current: 28.2

9.64
402.35
Forward P/E 22.32
SNY's Forward P/E is ranked higher than
86% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.14 vs. SNY: 22.32 )
N/A
PE(NRI) 28.10
SNY's PE(NRI) is ranked higher than
85% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.50 vs. SNY: 28.10 )
SNY' s 10-Year PE(NRI) Range
Min: 9.82   Max: 428.21
Current: 28.1

9.82
428.21
P/B 2.30
SNY's P/B is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. SNY: 2.30 )
SNY' s 10-Year P/B Range
Min: 1.11   Max: 5.98
Current: 2.3

1.11
5.98
P/S 3.50
SNY's P/S is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.01 vs. SNY: 3.50 )
SNY' s 10-Year P/S Range
Min: 1.77   Max: 5.22
Current: 3.5

1.77
5.22
PFCF 15.50
SNY's PFCF is ranked higher than
95% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 15.50 )
SNY' s 10-Year PFCF Range
Min: 4.49   Max: 45.57
Current: 15.5

4.49
45.57
POCF 12.25
SNY's POCF is ranked higher than
93% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.53 vs. SNY: 12.25 )
SNY' s 10-Year POCF Range
Min: 3.91   Max: 23.75
Current: 12.25

3.91
23.75
EV-to-EBIT 18.72
SNY's EV-to-EBIT is ranked higher than
87% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. SNY: 18.72 )
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5   Max: 204.2
Current: 18.72

10.5
204.2
Shiller P/E 24.80
SNY's Shiller P/E is ranked higher than
90% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 103.75 vs. SNY: 24.80 )
SNY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 25.2
Current: 24.8

13.35
25.2
Days Inventory 163.62
SNY's Days Inventory is ranked higher than
60% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.90 vs. SNY: 163.62 )
SNY' s 10-Year Days Inventory Range
Min: 155.87   Max: 224.59
Current: 163.62

155.87
224.59
Days Sales Outstanding 77.80
SNY's Days Sales Outstanding is ranked higher than
53% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.97 vs. SNY: 77.80 )
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29   Max: 103.32
Current: 77.8

61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.90
SNY's Dividend Yield is ranked higher than
93% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. SNY: 3.90 )
SNY' s 10-Year Dividend Yield Range
Min: 1.41   Max: 5.46
Current: 3.9

1.41
5.46
Dividend Payout 0.90
SNY's Dividend Payout is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. SNY: 0.90 )
SNY' s 10-Year Dividend Payout Range
Min: 1.17   Max: 8.15
Current: 0.9

1.17
8.15
Dividend growth (3y) 4.90
SNY's Dividend growth (3y) is ranked higher than
63% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. SNY: 4.90 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.1
Current: 4.9

0
22.1
Yield on cost (5-Year) 5.24
SNY's Yield on cost (5-Year) is ranked higher than
87% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. SNY: 5.24 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.9   Max: 7.34
Current: 5.24

1.9
7.34
Share Buyback Rate -0.80
SNY's Share Buyback Rate is ranked higher than
100% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.90 vs. SNY: -0.80 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
SNY's Price/DCF (Projected) is ranked higher than
94% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.24 vs. SNY: 1.20 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.47   Max: 5.65
Current: 1.2

0.47
5.65
Price/Median PS Value 1.20
SNY's Price/Median PS Value is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. SNY: 1.20 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 8.62
Current: 1.2

0.64
8.62
Earnings Yield (Greenblatt) 5.30
SNY's Earnings Yield (Greenblatt) is ranked higher than
86% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 5.30 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.5
Current: 5.3

0.5
9.5
Forward Rate of Return (Yacktman) 2.90
SNY's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.94 vs. SNY: 2.90 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.8   Max: 59.9
Current: 2.9

2.8
59.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SANNV.France, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 
Dodge & Cox's Stock Fund Q4 2014 Commentary Jan 20 2015 
Guru Stocks at 52-Week Lows: GOOG, VZ, HSBC, SNY, TOT Jan 12 2015 
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and It Jan 02 2015 
Guru Stocks at 52-Week Lows: HSBC, SNY, WBK, DCM, BBVA Dec 23 2014 


More From Other Websites
Top FDA Official Says Orexigen Study Result 'Unreliable,' 'Misleading' Mar 05 2015
Kidney treatment developer Tricida raises $30M in Series B Mar 05 2015
Regulators Want Drug Companies to Be Honest About FDA Mar 04 2015
Johnson & Johnson's Zytiga May Get a Boost Mar 03 2015
Fighting dengue fever with genetically-modified mosquito ... Mar 03 2015
Goldman Downgrades MannKind To Sell, Should You Follow Their Lead? Mar 03 2015
Why MannKind Could Lose Half Its Value Mar 03 2015
NOTICE TO SANOFI EMPLOYEES: Zamansky LLC Investigates Sanofi’s U. S. Group Savings Plan For... Mar 03 2015
If You 'Want To Make A Good Drug Great' Cost Must Be Factored In Mar 03 2015
MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch Mar 03 2015
Looking for European Dividends? Say Oui to the France ETF Mar 02 2015
MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter Mar 02 2015
What structural reforms are required by different countries? Feb 27 2015
Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Feb 27 2015
Who Might Buy Puma Biotechnology? Feb 27 2015
Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Feb 27 2015
Afrezza's Initial Sales Create Buying Opportunity Feb 27 2015
What You Should Know Before Watching Vice's Special About Curing Cancer Feb 26 2015
MannKind: 'Encouraged By Early Feedback' on Afrezza Launch Feb 26 2015
BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK